This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • Inhibiting high-risk corneal allografts

Inhibiting high-risk corneal allografts
Reviewed by Graham Wallace

1 October 2014 | Graham Wallace | EYE - Cornea, EYE - General | T regulatory cells, Tim-1, high-risk corneal allograft rejection, mice

The cornea is an immune privileged site and as such corneal transplants are very successful. However, in situations where this privilege is lost the failure rises substantially. To combat rejection inhibition of the immune responses depends on steroids and other immunosuppressive drugs, which are not always successful and sometimes have severe side-effects. In this paper the T cell receptor immunoglobulin and mucin domain (Tim) family member Tim1 was investigated. Tim1 is not expressed in naive CD4+ but is upregulated on the cell surface when activated, particularly on Th2 cells that are normally involved in allergic responses. To induce a high-risk transplant Balb/c mice were transplanted with corneas from C57BL/6 mice, which have different transplantation antigens and so will be recognised as foreign. Transplanted mice were either treated with RMT1-10, an anti-Tim1 monoclonal antibody or an isotype control. In RMT1-10 treated mice the numbers of effector immune cells were significantly decreased while T regulatory cells were significantly increased in the spleen, and allograft survival and corneal opacity were significantly increased. In vitro studies showed reduced expression of both IFN-Y and IL-4 in splenic CD4+ T cells from RMT1-10 treated animals. By comparison, expression of TGF-ß1, an anti-inflammatory cytokine was increased. Finally, RMT1-10 treated cells inhibited the delayed-type hypersensitivity in recipient mice, a model which supports a regulatory effect. The results suggest that inhibition of Tim1 can increase the regulatory arm of the immune response and decrease the inflammatory response, leading to increased allograft survival. The potential for such treatment in humans is of interest as unlike many diseases the timing of graft delivery and rejection is known and therefore delivery of inhibitory molecules easily determined.

Tim-1 blockade with RMT1-10 increases T regulatory cells and prolongs the survival of high-risk corneal allografts in mice.
Tan X, Jie Y, Zhang Y, et al.
EXPERIMENTAL EYE RESEARCH
2014;122(5):86-93.
Share This
CONTRIBUTOR
Graham Wallace

Birmingham and Midland Eye Centre, Birmingham, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency